File downloaded on 2026-11-09
Source URL: https://medicines.health.europa.eu/veterinary/en/600000027600

Suiseng Diff/A (--) - Suspension for injection

Authorised

- Clostridium difficile toxoid A
- Clostridium difficile toxoid B
- Clostridium perfringens, type A, alpha toxoid

Product identification

Medicine name:
Suiseng Diff/A (--) - Suspension for injection

Active substance:
Clostridium difficile toxoid A

Clostridium difficile toxoid B

Clostridium perfringens, type A, alpha toxoid

Target species:
Pig

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Clostridium difficile toxoid A

Presentation_strength:RP ≥ 1.60 Reference:Hse Index:0
Clostridium difficile toxoid B
Presentation_strength:RP ≥ 1.65 Reference:Hse Index:1
Clostridium perfringens, type A, alpha toxoid
Presentation_strength:RP ≥ 1.34 Reference:Hse Index:2

Pharmaceutical form:
Suspension for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Pig**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI09AB12

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:Vial (PET), Package_size:1 vial, Content:20 ml (10 doses)
Packaging:Vial (PET), Package_size:1 vial, Content:50 ml (10 doses)
Packaging:Vial (PET), Package_size:1 vial, Content:50 ml (25 doses)
Packaging:Vial (PET), Package_size:1 vial, Content:100 ml (25 doses)
Packaging:Vial (PET), Package_size:1 vial, Content:100 ml (50 doses)
Packaging:Vial (PET), Package_size:1 vial, Content:250 ml (50 doses)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Laboratorios Hipra S.A.

Marketing authorisation date:
7/12/2021

Manufacturing sites for batch release:
Laboratorios Hipra S.A.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
7/12/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 13/03/2026

Download

ema-puar-suiseng-diff-a-v-5596-par-en.pdf